{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T10:44:36Z","timestamp":1704192276874},"reference-count":29,"publisher":"FapUNIFESP (SciELO)","issue":"suppl 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  Intestinal secretagogues have been tested for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. The class-effect of these type of drugs has not been studied.  OBJECTIVE:  To determine the efficacy and safety of intestinal secretagogues for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome.  METHODS:  A computer-based search of papers from 1966 to September 2017 was performed. Search strategy consisted of the following MESH terms: intestinal secretagogues OR linaclotide OR lubiprostone OR plecanatide OR tenapanor OR chloride channel AND chronic constipation OR irritable bowel syndrome. Data were extracted as intention-to-treat analyses. A random-effects model was used to give a more conservative estimate of the effect of individual therapies, allowing for any heterogeneity among studies. Outcome measures were described as Relative Risk of achieving an improvement in the symptom under consideration.  RESULTS:  Database Search yielded 520 bibliographic citations: 16 trials were included for analysis, which enrolled 7658 patients. Twelve trials assessed the efficacy of intestinal secretagogues for chronic constipation. These were better than placebo at achieving an increase in the number of complete spontaneous bowel movements per week [RR 1.87 (1.24-2.83)], at achieving three or more spontaneous bowel movements per week [RR 1.56 (1.31-1.85)] and at inducing spontaneous bowel movement after medication intake [RR 1.49 (1.07-2.06)]. Similar results were observed when assessing the efficacy of intestinal secretagogues on constipation-predominant irritable bowel syndrome based on the results of six trials.  CONCLUSION:  Intestinal secretagogues are useful and safe therapeutic alternatives for the treatment of constipation-related syndromes.<\/jats:p>","DOI":"10.1590\/s0004-2803.201800000-41","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T15:36:02Z","timestamp":1533396962000},"page":"2-12","source":"Crossref","is-referenced-by-count":6,"title":["EFFICACY AND SAFETY OF INTESTINAL SECRETAGOGUES FOR CHRONIC CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS"],"prefix":"10.1590","volume":"55","author":[{"given":"Juan Sebastian","family":"LASA","sequence":"first","affiliation":[{"name":"Hospital Britanico de Buenos Aires,  Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Josefina","family":"ALTAMIRANO","sequence":"additional","affiliation":[{"name":"Hospital Britanico de Buenos Aires,  Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Florez","family":"BRACHO","sequence":"additional","affiliation":[{"name":"Hospital Britanico de Buenos Aires,  Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvina","family":"PAZ","sequence":"additional","affiliation":[{"name":"Hospital Britanico de Buenos Aires,  Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"ZUBIAURRE","sequence":"additional","affiliation":[{"name":"Hospital Britanico de Buenos Aires,  Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2018,8,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/2050640615600114","article-title":"Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population","volume":"4","author":"Vakil N","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5939238","DOI":"10.1155\/2016\/5939238","article-title":"Somatic comorbidity in chronic constipation: more data from the GECCO study","volume":"2016","author":"Enck P","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional Gastrointestinal Disorders: history, pathophysiology, clinical features and Rome IV","author":"Drossman DA","year":"2016","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann GJ","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","first-page":"8898","article-title":"Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies","volume":"20","author":"Jadallah KA","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref6","first-page":"32","article-title":"Clinical practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult","volume":"108","author":"Mearin F","year":"2016","journal-title":"Rev Esp Enferm Dig"},{"issue":"1","key":"ref7","article-title":"Cisapride for intestinal constipation","author":"Aboumarzouk OM","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5217\/ir.2015.13.4.297","article-title":"Recent updates on the treatment of constipation","volume":"13","author":"Ryu HS","year":"2015","journal-title":"Intest Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2146\/ajhp130575","article-title":"Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome","volume":"71","author":"Love BL","year":"2014","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"ref10","article-title":"ClC-2 regulation of intestinal barrier function: translation of basic science to therapeutic target","volume":"3","author":"Jin Y","year":"2015","journal-title":"Tissue Barriers"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/phar.1594","article-title":"Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents","volume":"35","author":"Thomas RH","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0016-5085(98)70439-1","article-title":"An evidence-based approach to gastroenterology therapy","volume":"114","author":"Schoenfeld P","year":"1998","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/j.gastro.2010.08.041","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","volume":"139","author":"Johnston JM","year":"2010","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2009.12.050","article-title":"Efficacy of linaclotide for patients with chronic constipation","volume":"138","author":"Lembo AJ","year":"2010","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJMoa1010863","article-title":"Two randomized trials of linaclotide for chronic constipation","volume":"365","author":"Lembo AJ","year":"2011","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey WD","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","article-title":"A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation","volume":"107","author":"Rao SS","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation","volume":"103","author":"Johanson JF","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman DA","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2982.2011.01668.x","article-title":"Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study","volume":"23","author":"Fukudo S","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182574f28","article-title":"Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease","volume":"78","author":"Ondo WG","year":"2012","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/pme.12437","article-title":"A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain","volume":"15","author":"Cryer B","year":"2014","journal-title":"Pain Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cgh.2014.08.026","article-title":"Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation","volume":"13","author":"Fukudo S","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ajg.2015.106","article-title":"A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain","volume":"110","author":"Jamal MM","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ajg.2016.531","article-title":"A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients","volume":"112","author":"Christie J","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ajg.2016.611","article-title":"A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation","volume":"112","author":"Miner PB","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/ajg.2017.41","article-title":"Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial","volume":"112","author":"Chey WD","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ref28","first-page":"CD007570","article-title":"Lactulose versus polyethylene glycol for chronic constipation","volume":"7","author":"Lee-Robichaud H","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gutjnl-2016-311835","article-title":"Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis","volume":"66","author":"Nelson AD","year":"2017","journal-title":"Gut"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v55s1\/1678-4219-ag-s0004280320180000041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T16:07:34Z","timestamp":1545408454000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032018000500002&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,6]]},"references-count":29,"journal-issue":{"issue":"suppl 1","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["S0004-28032018000500002"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.201800000-41","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,6]]}}}